ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Prognostic value of integrating CT morphological features and PET volumetric metabolic parameters in surgically resected stage IA non-small cell lung cancer: a two-center retrospective study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBoth ground-glass opacity (GGO) components on computed tomography (CT) and metabolic information derived from positron emission tomography (PET) are associated with prognosis in early‑stage non-small cell lung cancer (NSCLC) patients. The purpose of this study was to evaluate whether their combined assessment could improve risk stratification in surgically resected stage IA NSCLC.
methodsWe retrospectively analyzed 212 consecutive patients with stage IA NSCLC from two medical centers who underwent 18F-FDG PET/CT before curative surgery between November 2012 and October 2024. The cohort was divided into feasibility evaluation (n = 152) and external validation (n = 60) groups. Primary tumor maximum standardized uptake values (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured. Optimal PET parameter cutoffs for progression-free survival (PFS) were determined using receiver operating characteristic curve analysis in the feasibility cohort. A two-point prognostic scoring system combining GGO features and the multivariable-identified prognostic PET parameters was developed and validated in both cohorts using log-rank tests.
resultsFor the feasibility cohort, the optimal cut-off values for the prediction of PFS were 6.2, 1.9 mL, and 11.7 for SUVmax, MTV, and TLG, respectively. Both patients with primary tumors exceeding these metabolic parameters and those in the GGO-negative subgroup showed significantly shorter PFS (all P < 0.05). Multivariable analysis identified GGO [hazard ratio (HR) = 8.137; 95% CI: 1.035–63.998; P = 0.046] and TLG (HR = 4.993; 95% CI: 1.831–13.612; P = 0.002) as independent prognostic factors, even after adjusting for histopathology and other PET parameters. The two-point prognostic scoring system, which consisted of GGO and TLG, stratified patients into low-, moderate-, and high-risk groups. In the feasibility cohort, PFS demonstrated statistically significant differences between the three groups (all P < 0.05), with similar trends in the external validation cohort.
conclusionsThe two-point prognostic scoring system, combining morphological GGO features with volumetric metabolic parameters TLG, provided a simple yet effective method for enhancing prognostic stratification in patients with surgically resected stage IA NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.